The crystal structure of human abl1 kinase domain in complex with DCC-2036

Experimental Data Snapshot

  • Resolution: 2.10 Å
  • R-Value Free: 0.272 
  • R-Value Work: 0.213 
  • R-Value Observed: 0.216 

wwPDB Validation   3D Report Full Report

Ligand Structure Quality Assessment 

This is version 1.2 of the entry. See complete history


Conformational Control Inhibition of the BCR-ABL1 Tyrosine Kinase, Including the Gatekeeper T315I Mutant, by the Switch-Control Inhibitor DCC-2036.

Chan, W.W.Wise, S.C.Kaufman, M.D.Ahn, Y.M.Ensinger, C.L.Haack, T.Hood, M.M.Jones, J.Lord, J.W.Lu, W.P.Miller, D.Patt, W.C.Smith, B.D.Petillo, P.A.Rutkoski, T.J.Telikepalli, H.Vogeti, L.Yao, T.Chun, L.Clark, R.Evangelista, P.Gavrilescu, L.C.Lazarides, K.Zaleskas, V.M.Stewart, L.J.Van Etten, R.A.Flynn, D.L.

(2011) Cancer Cell 19: 556-568

  • DOI: https://doi.org/10.1016/j.ccr.2011.03.003
  • Primary Citation of Related Structures:  
    3QRI, 3QRJ, 3QRK

  • PubMed Abstract: 

    Acquired resistance to ABL1 tyrosine kinase inhibitors (TKIs) through ABL1 kinase domain mutations, particularly the gatekeeper mutant T315I, is a significant problem for patients with chronic myeloid leukemia (CML). Using structure-based drug design, we developed compounds that bind to residues (Arg386/Glu282) ABL1 uses to switch between inactive and active conformations. The lead "switch-control" inhibitor, DCC-2036, potently inhibits both unphosphorylated and phosphorylated ABL1 by inducing a type II inactive conformation, and retains efficacy against the majority of clinically relevant CML-resistance mutants, including T315I. DCC-2036 inhibits BCR-ABL1(T315I)-expressing cell lines, prolongs survival in mouse models of T315I mutant CML and B-lymphoblastic leukemia, and inhibits primary patient leukemia cells expressing T315I in vitro and in vivo, supporting its clinical development in TKI-resistant Ph(+) leukemia.

  • Organizational Affiliation

    Molecular Oncology Research Institute, Tufts Medical Center, Boston, MA 02111, USA.

Find similar proteins by:  (by identity cutoff)  |  3D Structure
Entity ID: 1
MoleculeChains Sequence LengthOrganismDetailsImage
Tyrosine-protein kinase ABL1
A, B
277Homo sapiensMutation(s): 0 
Gene Names: ABL1ABLJTK7
UniProt & NIH Common Fund Data Resources
Find proteins for P00519 (Homo sapiens)
Explore P00519 
Go to UniProtKB:  P00519
PHAROS:  P00519
GTEx:  ENSG00000097007 
Entity Groups  
Sequence Clusters30% Identity50% Identity70% Identity90% Identity95% Identity100% Identity
UniProt GroupP00519
Sequence Annotations
  • Reference Sequence
Small Molecules
Binding Affinity Annotations 
IDSourceBinding Affinity
919 BindingDB:  3QRI Kd: 7.2 (nM) from 1 assay(s)
Binding MOAD:  3QRI IC50: 0.8 (nM) from 1 assay(s)
PDBBind:  3QRI IC50: 0.8 (nM) from 1 assay(s)
Experimental Data & Validation

Experimental Data

  • Resolution: 2.10 Å
  • R-Value Free: 0.272 
  • R-Value Work: 0.213 
  • R-Value Observed: 0.216 
  • Space Group: P 1 21 1
Unit Cell:
Length ( Å )Angle ( ˚ )
a = 60.26α = 90
b = 59.7β = 108.71
c = 79.43γ = 90
Software Package:
Software NamePurpose
BOSdata collection
HKL-2000data reduction
HKL-2000data scaling

Structure Validation

View Full Validation Report

Ligand Structure Quality Assessment 

Entry History 

Revision History  (Full details and data files)

  • Version 1.0: 2011-06-01
    Type: Initial release
  • Version 1.1: 2011-07-13
    Changes: Version format compliance
  • Version 1.2: 2024-02-21
    Changes: Data collection, Database references, Derived calculations